臨床泌尿器科71巻5号

2017年04月発行

綜説

腎細胞癌における分子標的薬の薬物動態学，薬力学，ゲノム薬理学

著者： 土谷順彦¹

所属機関： ¹山形大学医学部腎泌尿器外科学講座

ページ範囲：P.291 - P.297

文献概要

要旨

　現在，腎細胞癌の薬物療法としてチロシンキナーゼ阻害剤（TKI）やmTOR阻害剤（mTORI）が用いられている．これらの治療薬は高い治療効果を有する一方，しばしば重篤な有害事象を引き起こす．通常，このような薬剤には血中濃度モニタリングが行われることが多いが，がん領域においてはほとんど行われることがない．経口薬は吸収の影響を大きく受けるため，血中濃度測定によって効果や有害事象を予測し，個々の患者に適した用量調整ができる可能性がある．また，薬物関連遺伝子多型の薬物血中濃度への影響も明らかになってきた．本稿では，腎細胞癌に対する薬物療法における薬物動態，薬力学そしてゲノム薬理学について解説する．

参考文献

1） Escudier B, Pluzanska A, Koralewski P, et al : Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial. Lancet 370 : 2103─2111, 2007

2） Escudier B, Eisen T, Stadler WM, et al : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 : 125─134, 2007

3） Motzer RJ, Hutson TE, Tomczak P, et al : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 : 115─124, 2007

4） Rini BI, Escudier B, Tomczak P, et al : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma （A XI S） : a randomised phase 3 trial. Lancet 378 : 1931─1939, 2011

5） Sternberg CN, Davis ID, Mardiak J, et al : Pazopanib in locally advanced or metastatic renal cell carcinoma : results of a randomized phase III trial. J Clin Oncol 28 : 1061─1068, 2010

6） Hudes G, Carducci M, Tomczak P, et al : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 : 2271─2281, 2007

7） Motzer RJ, Escudier B, Oudard S, et al : Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 : 449─456, 2008

8） Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443─2454, 2012

9） Brahmer JR, Tykodi SS, Chow LQ, et al : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 : 2455─2465, 2012

10） Wolchok JD, Kluger H, Callahan MK, et al : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 : 122─133, 2013

11） Blanchet B, Billemont B, Cramard J, et al : Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49 : 1109─1114, 2009

12） Shimada M, Okawa H, Kondo Y, et al : Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. Tohoku J Exp Med 237 : 173─182, 2015

13） de Wit D, Guchelaar HJ, den Hartigh J, et al : Individualized dosing of tyrosine kinase inhibitors : are we there yet? Drug Discov Today 20 : 18─36, 2015

14） Bins S, Lenting A, El Bouazzaoui S, et al : Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics 17 : 1483─1490, 2016

15） Tsuchiya N, Narita S, Inoue T, et al : Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs 24 : 310─314, 2013

16） Houk BE, Bello CL, Poland B, et al : Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer : results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66 : 357─371, 2010

17） Faivre S, Delbaldo C, Vera K, et al : Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 : 25─35, 2006

18） Diekstra MH, Klumpen HJ, Lolkema MP, et al : Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther 96 : 81─89, 2014

19） van der Veldt AA, Eechoute K, Gelderblom H, et al : Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17 : 620─629, 2011

20） Diekstra MH, Swen JJ, Boven E, et al : CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol 68 : 621─629, 2015

21） Mizuno T, Fukudo M, Terada T, et al : Impact of genetic variation in breast cancer resistance protein （BCRP/ABCG2） on sunitinib pharmacokinetics. Drug Metab Pharmacokinet 27 : 631─639, 2012

22） Narjoz C, Cessot A, Thomas-Schoemann A, et al : Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs 33 : 257─268, 2015

23） Low SK, Fukunaga K, Takahashi A, et al : Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PLoS One 11 : e0148177, 2016

24） Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al : Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib : a multicentre, observational, prospective study. Lancet Oncol 12 : 1143─1150, 2011

25） Rini BI, Melichar B, Ueda T, et al : Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma : a randomised double-blind phase 2 trial. Lancet Oncol 14 : 1233─1242, 2013

26） Rini BI, Tomita Y, Melichar B, et al : Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 14 : 499─503, 2016

27） Rini BI, Garrett M, Poland B, et al : Axitinib in metastatic renal cell carcinoma : results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol 53 : 491─504, 2013

28） Rini BI, Melichar B, Fishman MN, et al : Axitinib dose titration : analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 26 : 1372─1377, 2015

29） Brennan M, Williams JA, Chen Y, et al : Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 68 : 645─655, 2012

30） Suttle AB, Ball HA, Molimard M, et al : Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111 : 1909─1916, 2014

31） de Wit D, van Erp NP, den Hartigh J, et al : Therapeutic drug monitoring to individualize the dosing of pazopanib : a pharmacokinetic feasibility study. Ther Drug Monit 37 : 331─338, 2015

32） Heath EI, Chiorean EG, Sweeney CJ, et al : A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88 : 818─823, 2010

33） Tanaka A, Yano I, Shinsako K, et al : Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma. Ther Drug Monit 38 : 663─669, 2016

34） Shinsako K, Yano I, Tanaka A, et al : Everolimus blood concentrations did not predict interstitial lung disease in patients with metastatic renal cell carcinoma. Jpn J Ther Drug Monit 33 : 1─8, 2016

35） Kovarik JM, Hartmann S, Figueiredo J, et al : Effect of food on everolimus absorption : quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 22 : 154─159, 2002

36） Picard N, Rouguieg-Malki K, Kamar N, et al : CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 91 : 652─656, 2011

37） Schoeppler KE, Aquilante CL, Kiser TH, et al : The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant 28 : 590─597, 2014

38） Kniepeiss D, Renner W, Trummer O, et al : The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 25 : 146─150, 2011

39） Bodnar L, Stec R, Cierniak S, et al : Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. Ann Oncol 26 : 1385─1389, 2015

40） Atkins MB, Hidalgo M, Stadler WM, et al : Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 : 909─918, 2004

41） Brahmer JR, Drake CG, Wollner I, et al : Phase I study of single-agent anti-programmed death-1 （MDX-1106） in refractory solid tumors : safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 : 3167─3175, 2010

42） Nivolumab MUE and dosing recommendations.　http://central.hoparx.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=79eb2680-2431-48f7-8740-99fc2526dbd5 （2016年11月1日現在）